Found 4 matching trials
Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
PHASE1This study is designed to evaluate safety and antitumor activity of DZD6008...
Location
Peking Union Medical College Hospital
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
PHASE1This study is designed to evaluate safety and anti-tumor activity of DZD600...
Location
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
PHASE1This study is designed to evaluate safety and antitumor activity of DZD6008...
Location
Shanghai Chest Hospital
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
PHASE1This study will treat patients with advanced NSCLC harboring EGFR mutations...
Location
Beijing Chest Hospital